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Abstract
Recent advances in nucleic acid sequencing technologies, referred to as ‘next-generation’ sequencing (NGS), have produced a true
revolution and opened new perspectives for research and diagnostic applications, owing to the high speed and throughput of data
generation. So far, NGS has been applied to metagenomics-based strategies for the discovery of novel viruses and the characterization of
viral communities. Additional applications include whole viral genome sequencing, detection of viral genome variability, and the study of viral
dynamics. These applications are particularly suitable for viruses such as human immunodeﬁciency virus, hepatitis B virus, and hepatitis C
virus, whose error-prone replication machinery, combined with the high replication rate, results, in each infected individual, in the formation
of many genetically related viral variants referred to as quasi-species. The viral quasi-species, in turn, represents the substrate for the
selective pressure exerted by the immune system or by antiviral drugs. With traditional approaches, it is difﬁcult to detect and quantify
minority genomes present in viral quasi-species that, in fact, may have biological and clinical relevance. NGS provides, for each patient, a
dataset of clonal sequences that is some order of magnitude higher than those obtained with conventional approaches. Hence, NGS is an
extremely powerful tool with which to investigate previously inaccessible aspects of viral dynamics, such as the contribution of different viral
reservoirs to replicating virus in the course of the natural history of the infection, co-receptor usage in minority viral populations harboured
by different cell lineages, the dynamics of development of drug resistance, and the re-emergence of hidden genomes after treatment
interruptions. The diagnostic application of NGS is just around the corner.
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Next-generation Sequencing: Principles and
Methods
Recent advances in the nucleic acid sequencing technologies,
referred to as ‘next-generation’ sequencing (NGS), have
produced a true revolution and opened new perspectives
for research and diagnostic applications. One of the hallmark
features of the NGS technologies is their massive throughput
at a modest cost, with hundreds of gigabases of sequencing
now being possible in a single run for some thousand dollars.
The ﬁrst commercially available NGS system, developed by
454 Life Sciences, appeared in 2005. Since then, in a relatively
short time, several NGS technologies have been developed
(Table 1). According to the different characteristics, the
spectrum of application of the platforms may show signiﬁcant
differences. In particular, the systems can be referred to as:
high-capacity sequencers, such as the Genome Analyzer, HiSeq
sequencers (Illumina, San Diego, CA, USA), the Heliscope
platform (Helicos BioSciences Corporation, Cambridge, MA,
USA) and 5500 series sequencers, which use SOLiD technol-
ogy (Applied Biosystems, Carlsbad, CA, USA); and long-read
sequencers, such as the Genome Sequencer (GS) FLX or
Junior (454 Life Sciences, Roche Diagnostics, Branford, CT,
USA), Ion Torrent (Applied Biosystems), and PacBio RS
(Paciﬁc Biosciences, Gen-Probe, Menlo Park, CA, USA).
Current NGS methods use a three-step sequencing pro-
cess: library preparation, DNA capture and enrichment, and
sequencing/detection [1]. In library preparation, DNA (or
cDNA) fragments of appropriate lengths are prepared, by
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either breaking long molecules, or by synthetically preparing
short molecules (i.e. by PCR or cloning). In the DNA capture
and enrichment phase, these short molecules are labelled with
primers that are used to capture and physically separate each
single short fragment, ﬁxing it onto a solid substrate. Each
single molecule acts as a template for clonal ampliﬁcation
(single-molecule template principle). The sequencing phase is
based on DNA polymerization combined with detection.
These steps occur concomitantly on myriads of clonally
ampliﬁed fragments. In some of the platforms, the PCR step
is not required, and sequencing is performed on single
(Helicos) or on linearly ampliﬁed (PacBio RS) molecules. The
principles for the sequencing/detection phase are different in
the various platforms: pyrophosphate release (pyrosequenc-
ing) coupled with optical detection of ﬂuorescence, hydrogen
ion release coupled with detection of pH variation by a
semiconductor, ligation combined with ﬂuorescence detec-
tion, and linear ampliﬁcation coupled with ﬂuorescence
detection. The detected signals are transformed into
sequences by an integrated browser and elaborated with
speciﬁc software, to match pre-established quality scores.
Bioinformatic tools for the evaluation and elaboration of the
sequence data are in continuous development, according to
the various applications.
There are many factors involved in the choice of
technology, including cost performance, run time, accessibil-
ity, type of application, and convenience. More detailed
descriptions of the technical features of NGS methods are
given in [2–6].
NGS Applications to Virology
NGS applications to virology have been recently reviewed [7–
10]. Some of the topics relevant for clinical application will be
brieﬂy described.
Virus discovery (metagenomics)
The term metagenomics designates the analysis of all of the
nucleic acid present in a given sample, allowing the exploration
of entire communities of microorganisms, and avoiding the
need to isolate and culture individual microbial species, and
does not need previous knowledge of the sequences.
This new science is one of the fastest advancing ﬁelds in
biology, and is extending our comprehension of the diversity,
ecology, evolution and functioning of the microbial world, as
well as contributing to the emergence of new applications in
many different areas. Several large projects have been funded
in the USA or EU for the deﬁnition of the human microbiome
based on metagenomics (e.g. the Human Microbiome Project,T
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funded by the NIH, and Metagenomics of the Human Intestinal
Tract, funded by the EU).
The continuous and dynamic development of NGS repre-
sents an unprecedented opportunity for metagenomic appli-
cations, and is expanding our capacity to analyse microbial
communities from a variety of habitats and environments
[3,11]. In this respect, unbiased massively parallel sequencing is
the term used to designate NGS metagenomic applications.
Metagenomic applications of NGS include the discovery of
novel viruses from clinical samples in human and animal
diseases, e.g. a new arenavirus involved in transplant-associ-
ated disease clusters [12], and the new Ebola virus Bundi-
ubugyo [13], and the identiﬁcation of a viral aetiology of an
outbreak of a disease in honeybees [14]. NGS is also applied
for the characterization of the virome, i.e. of the viral
community, in the environment [15,16], in animals [17], and
in humans [18–21].
Whole viral genome reconstruction
The reconstruction of full-length viral genomes, even in the
case of unknown or poorly characterized viruses, is a common
application of NGS, starting either from culture-enriched viral
preparations, or directly from clinical samples. The assay
design can vary from shotgun metagenomic sequencing of
random libraries, to random shotgun sequencing of full
genome amplicons, to overlapping amplicon sequencing and
assembly.
These approaches have been used to obtain full genome
sequencing of pandemic inﬂuenza virus [22–26], human
immunodeﬁciency virus (HIV) [27,28], human herpesviruses
[29,30], and other viruses. Besides the reconstruction of the
viral genomes, in most of these studies evaluation of intra-host
virus variability has also been achieved, thanks to the high
coverage of single-nucleotide positions allowed by massively
parallel sequencing (see also next paragraph).
Characterization of intra-host variability
RNA viruses, such as hepatitis C virus (HCV) and inﬂuenza
virus, and reverse transcriptase-dependent viruses, such as
hepatitis B virus (HBV) and HIV, show high intra-host
variability. This is the result of high replication capacity and
low ﬁdelity of the replication enzyme (ranging from 105 to
103 substitutions/position/cycle). So, whereas a single foun-
der virus often dominates in the early stages of infection,
during the subsequent phases a great number of mutations
emerge spontaneously. These mutations are rapidly lost if they
lead to replication disadvantage, they may either disappear or
progressively accumulate as result of casual drift if they are
neutral, or they are rapidly ﬁxed if they confer selective
advantage. The highly variable mixture of closely related
genomes within a given host, referred to as quasi-species,
allows a viral population to rapidly adapt to dynamic environ-
ments and evolve resistance to vaccines and antiviral drugs
[31]. NGS has been widely used for the characterization of
intra-host variability of inﬂuenza virus [23,32], HCV, HIV and
HBV. Most of these studies have been based on ultradeep
sequencing (UDS) of PCR-generated amplicons spanning the
genomic region(s) of interest. The main studies on HCV, HIV
and HBV are reviewed below.
HCV. Owing to the high replication rate of HCV and to the
error-prone nature of RNA-dependent RNA polymerase,
many mutations are spontaneously generated every day, and
even the existence of two or three mutations in a single
genome is highly probable [33]. This phenomenon provides the
genetic background for the selection of mutants that are able
to escape immunological and therapeutic control. To date,
drug-related mutations that confer resistance to direct-acting
antiviral agents (DAAs) have been identiﬁed at several
positions in NS3/4A and in NS5. In the absence of selective
pressure (antiviral therapy), HCV variants bearing mutations
conferring resistance are generally present at a very low
frequency, making detection extremely challenging.
UDS can be used to identify such resistant variants prior to
treatment. Studies performed in vivo have shown that multiple
mutations pre-exist in the absence of DAA administration,
with an intrapatient frequency generally below 1%. [34–36]. In
another study, the estimate of the intrapatient frequency of
minority resistance mutations was slightly higher [32]. From
such studies, a dynamic pattern has emerged, whereby
resistance mutations frequently appear, but are rapidly lost
in the absence of selective pressure, because of reduced
ﬁtness. It has been suggested that not only the number but also
the nature of the nucleotide changes can contribute to the
genetic barrier to the development of resistance [37]. The
dynamics of the emergence of DAA resistance mutations
under selective pressure exerted by the new macrocyclic NS3/
4A protease inhibitor has been thoroughly investigated with an
in vitro replicon model, and this has shown the emergence and
disappearance of multiple replicon variants in response to the
changing selective pressure [38]. The kinetics of development
of DAA resistance in vivo have been studied in a human
hepatocyte chimeric mouse model, and this has shown the
rapid emergence of resistance mutations after the administra-
tion of single drugs [39].
HCV genome variation has also been studied at sites
different from DAA targets, such as the PKR-eIF2alpha
phosporylation homology domain, and this has shown no
correlation between mutations at this site and the response to
pegylated interferon and ribavirin [40]. A genome-wide
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 15–22
CMI Capobianchi et al. NGS in clinical virology 17
characterization of HCV conﬁrmed that E2, containing hyper-
variable region-1 and hypervariable region-2, is the most
variable region within individual patients, and that the response
to pegylated interferon + ribavirin is accompanied by a rapid
reduction of complexity in this region, which remains
unaffected in non-responding patients [35].
Other studies have addressed intra-host HCV evolution
during primary infection, and have highlighted the existence of
multiple bottlenecks during and shortly after the transmission
event [41,42], and ﬁne-tuning of the effects of immunological
pressure in the subsequent within-host evolution [43,44]. In
addition, UDS has been used to trace HCV transmission
among injection drug users [45].
HIV antiretroviral drug resistance. HIV is among the most
variable human pathogenic viruses. The main NGS applications
to HIV variability include the detection of resistance to
antiretroviral drugs and the characterization of genome
regions involved in tropism.
Two pioneer studies describing the application of NGS to
antiretroviral resistance mutations appeared in 2007 [46,47].
Subsequently, a number of studies appeared on both naı¨ve and
antiretroviral therapy-experienced patients. On the whole,
NGS was much more sensitive than Sanger sequencing in
identifying the patients harbouring mutations for almost all of
the classes of antiretroviral drug, roughly doubling the
estimates based on population sequencing. This was principally
attributable to low-abundance mutations, which were not
detectable with population-based sequencing. Overall, the
results of such studies indicate that low-abundance resis-
tance-associated mutations are unfavourable prognostic mark-
ers of therapy success, both in naı¨ve [48–50] and in experienced
patients [51–53]. Longitudinal analysis has been performed in
patients failing antiretroviral regimens, and has shown de novo
emergence and recombination between mutant genotypes [54].
In addition, in naı¨ve patients, reverse transcriptase (RT)
mutations that are not considered to be intrinsically relevant
for drug resistance, and that are not detectable by standard
sequencing, such as T69S and L210M, can act as ‘sentinels’ of the
presence of minority resistant variants in HIV-1 drug-naive
patients [55]. Insights into the transmission of resistance-
associated mutations have been provided by other studies [56].
HIV tropism. HIV tropism represents a key factor in disease
progression and severity. Several ﬁndings indicate that variants
using the CCR5 co-receptor (R5 variants) are preferentially
transmitted and predominate during the early stages of the
infection. CXCR4 co-receptor-using (X4) variants generally
emerge at later stages, although they can occasionally be found
during primary infection, and constitute a marker of a more
aggressive clinical course. Recently, a CCR5 antagonist (ma-
raviroc) has been introduced as an antiretroviral treatment
option, with the prerequisite that the HIV strain harboured by
candidate patients is not X4. This latter condition may be
established by phenotypic tropism testing, or by genotypic
methods. The latter methods are based on sequencing of the
V3 region of the env gene. The application of UDPS to V3
sequencing for the study of HIV tropism has been widely used
for the retrospective investigation of clinical trials based on
maraviroc [57–62]. The main results of such studies have
shown that UDS is very sensitive in identifying low-abundance
X4 variants. The possibility of obtaining quantitative data
allows monitoring of the shift of tropism in the viral population
during virological failure. A general concept that has emerged
from these studies is that minority X4 variants pre-exist and
outgrow the R5 variants during treatment in patients in whom
maraviroc administration fails without the development of
drug resistance mutations. Therefore, such studies have shown
that the availability of sensitive and quantitative methods with
which to identify rare X4 variants before the start maraviroc
administration is crucial, and is easily achieved with NGS.
NGS application to V3 sequencing has also provided insights
into viral dynamics. Studies from our group have shown that
this approach may unveil new scenarios in HIV pathogenesis.
We captured the circulating HIV virions with antibodies
against blood cell lineage markers to obtain viral progeny from
different host cells, and applied V3 UDPS to the viral genomes
obtained from this sorting procedure; with this approach, we
showed that proviral reservoirs in the monocyte lineage and
CD4 T-cells are the source of rebounding viruses after therapy
interruption[63]; this study also showed that minority X4
variants are more frequently detected in monocytes, and that
the viral quasi-species hosted by these cells is more complex
than that harboured by T-cells. The X4 provirus archived in
monocytes was identiﬁed as a putative source of replication-
competent virus [64]; however, the frequency of X4 variants
did not show a net increase within 6 months from therapy
suspension [65].
Furthermore, NGS showed that X4 variants are frequently
detected in patients with primary infection, accounting for up
to 50% of cases, and that viral diversity correlates directly with
the intrapatient frequency of X4 variants. Patients with high
diversity and high X4 frequency have a more aggressive clinical
presentation, and require early treatment [66]. Typical phylo-
genetic trees based on NGS V3 sequence data from patients
with primary infection who needed early treatment or not is
shown in Fig. 1, where the presence of polyphyletic X4
variants is only observed in the ﬁrst case.
In a recent study based on cloning and sequencing, the
degree of HIV diversiﬁcation was measured in patients from
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the Swiss Cohort prospectively followed since primary infec-
tion [67]. During primary infection, the median viral diversity
was low (0.39%), but it was >1% in 11% of the patients. Viral
diversity increased with time since infection, but no association
was observed between increased diversity and plasma HIV-1
RNA load or CD4 numbers. Most participants harboured R5
strains, and only a small percentage of CXCR4-using viruses
within a mixed population were detected in this cohort, in line
with our ﬁndings.
HBV. The application of NGS to the study of HBV resistance
was pioneered by our group in 2009 [68]. The presence of
minority variants harbouring major drug resistance mutations,
observed in this study for the ﬁrst time in naı¨ve patients, was
conﬁrmed by others [69]. Subsequent studies supported the
huge power of NGS for investigating the dynamics of drug
resistance mutations in the course of treatment, and showed
that minority mutations may exist before treatment start or
shift, and may expand in response to drug-driven selective
pressure [70–72].
One of the striking features of the HBV genome is the
overlap between the coding regions (open reading frames) for
polymerase and surface glycoprotein (hepatitis B surface
antigen (HBsAg)). We have observed a number of changes in
the HBsAg open reading frame, several of which led to stop
codons, whose frequency ranged between 1% and 3% [68]. In
fact, mutated virions that are not capable of coding for correct
HBsAg are expected to be strongly impaired, and their
maintenance in viral quasi-species should be dependent on the
concomitant presence of wild-type virions, as supported by a
recent report [73].
The driving force for selecting such variations presumably
acts differently on RT and HBsAg. Further studies are
necessary to clarify this point, and it is expected that NGS
will be extremely helpful in this.
Conclusions
The current revolution in microbiology has been primarily
driven by advances in technology and, in particular, by the
development of parallel sequencing platforms, which have led
to a substantial reduction in costs and a substantial increase in
throughput and accuracy. Not only does NGS provide
FIG 1. Phylogenetic trees of plasma-associated and peripheral blood mononuclear cells (PBMC)-associated human immunodeﬁciency virus (HIV)-1
from two representative patients with acute infection who harboured X4 variants (patient A received highly active antiretroviral therapy within
6 months after seroconversion, and patient B remained free of therapy). The phylogenetic trees indicated that X4 variants of patient A belonged to
distinct lineages, whereas, in patient B, X4 variants were monophyletic in the context of a star-like phylogeny. The trees were built with the V3
amino acid sequences obtained from UDPS, with the neighbour-joining method based on p-distance and 1000 bootstrap replicates as in MEGA
version 4.0 (www.megasoftware.net). The sequence correction pipeline was based on the translation of nucleotide sequences and conservation of
only the coding ones, as previously described [62,63]. The sequences were classiﬁed as X4 or R5 by use of the position-speciﬁc score matrix (PSSM)
algorithm, with the X4R5 matrix for subtype B HIV-1 (http://www.fortinbras.us/cgi-bin/fssm/fssm.pl).
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knowledge for basic research, but also it affords immediate
application beneﬁts, including improved diagnostics, prognos-
tics and therapy monitoring for many viral diseases.
The need to incorporate these technologies into the everyday
thinking of microbiologists, and especially those studying the role
that microorganisms play in the environment and in disease
development, has been driven by the inability to culture the
majority of microorganisms from an ecosystem and the logistics
of using a myriad of culture conditions to capture those that can
be grown in vitro. To this end, the development of culture-
independent methods has provided the scientiﬁc community
with paradigm-shifting revelations and opened up the world of
the microorganism to much more intensive investigation.
Sequence-independent methods are becoming more impor-
tant for the identiﬁcation of emerging viruses in a public health
context. Viral metagenomics is a relatively new technique that
has been used increasingly to identify viruses in clinical
specimens. In the diagnostic setting, metagenomic approaches
could be used for the systematic analysis of samples collected
from patients with unexplained illness, especially in the context
of outbreaks and epidemics. As mentioned above, the applica-
tion of high-throughput NGS methods in viral metagenomics
can greatly enhance the chance of identify viruses in clinical
samples, including viruses that are too divergent from known
viruses to be detected by PCR or microarray techniques.
In addition, the deep investigation of viral quasi-species by NGS
is substantially increasing our understanding of the dynamics of
viral infections and their interplay with the selective forces acting
during transmission bottlenecks, immune and drug pressure, etc.
In addition, the possibility of using barcoding systems for the
simultaneous analysis of multiple samples can substantially
reduce the cost of genotype resistance testing, and may
increase the throughput for large-scale population studies [47].
Therefore, it is highly probable that NGS will also be
exploited for clinical application in the analysis of drug
resistance for HIV, HCV, and HBV. We can also envisage that
ﬁne assessment of HIV tropism by NGS will be useful to obtain
prognostic disease markers during early stages of the infection
and before starting or switching antiviral treatment.
However, NGS is a relatively recent technique, and several
issues must be addressed before it can become fully exploit-
able at the clinical laboratory level.
In particular, the high cost of the equipment is a major
limiting factor. It is likely that the cost will decrease in the future
as the technology of deep sequencing develops. Lower-cost
systems have already been developed and deployed in advanced
clinical laboratories, such as the Junior equipment that will
rapidly replace the higher-scale GS platform from Roche.
Other major issues are access to the computational power
needed to analyse very large sequence datasets and the need
for skilled personnel with proper bioinformatic expertise.
These professionals should integrate existing bioinformatics
algorithms with high-performance computing solutions. How-
ever, although state-of-the-art NGS data analysis tools can
provide good precision, continuous improvement is funda-
mental to solve problems in a number of ﬁelds. First, technical
errors must be distinguished from real mutations. Indeed, it is
known that PCR polymerases typically have error rates of one
substitution per 105–106 bases. Furthermore, in the case of
454 GS-FLX titanium pyrosequencing, for instance, the mean
error rate can be as high as 1% [74].
As deep sequencing generates millions of reads from a given
sample, technology-intrinsic errors might be misinterpreted as
mutations or polymorphisms. This requires error identiﬁcation
and correction. Many algorithms have been designed to
increase the quality of data (PyroNoise clusters, SHORAH,
KEC, ET, etc.), but it is still not possible to obtain data free of
error. The use of platforms that do not require PCR
ampliﬁcation prior to sequencing (such as Helicos and
PacBio RS) may circumvent some of the problems resulting
from the PCR steps, such as primer selection and mutations
introduced during ampliﬁcation. However, due to the lack of
PCR, these platforms suffer from low signal strength (Table 1);
overall, these methods warrant further validation and inves-
tigations of their applicability in virology.
Another problem of data mining is that, at present, there
are no perfect alignment tools, and a compromise is generally
tolerated between alignment accuracy and time of analysis,
where appropriate hardware and software characteristics are
crucial.
The persistent problem of DNA contamination and the
medical signiﬁcance of the detection of very low levels of viral
nucleic acid will also need to be resolved. This will require
close collaboration between different areas of expertise, i.e.
bioinformatics and virology, for the development of an efﬁcient
pipeline of analysis and for validation of the results.
In conclusion, although the application of NGS to virology is
in its infancy, we can expect that its development will not only
help to shed light on viral pathogenesis, but will also lead to
practical applications in clinical diagnostic laboratories.
Equipment simpliﬁcation, method standardization and the
development of user-friendly bioinformatic tools are urgent
needs to be met in order to render the new, potent tool
represented by NGS more accessible to clinical virology.
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